

論文業績 (欧文) (査読あり)

1. Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y Dr, Hidaka T, Nosaka K, Sasaki H, Rai S, Tamura S, Owatari S, Koh KR, Nakamura D, Tokunaga M, Sekine M, Sakamoto Y, Inagaki H, **Ishida T**, Ishitsuka K. A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma. **Blood**. 2025 May 15: blood.2024027902. doi: 10.1182/blood.2024027902.
2. Sakamoto Y, **Ishida T**, Masaki A, Murase T, Ohtsuka E, Takeshita M, Muto R, Choi I, Iwasaki H, Ito A, Kusumoto S, Nakano N, Tokunaga M, Yonekura K, Tashiro Y, Suehiro Y, Iida S, Utsunomiya A, Ueda R, Inagaki H. Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma. **Int J Hematol**. 2025 Feb;121(2):206-221.
3. Nakashima T, Kusumoto S, **Ishida T**, Kato C, Hagiwara S, Narita T, Masaki A, Ito A, Ri M, Komatsu H, Inagaki H, Tanaka Y, Iida S. Fulminant hepatitis in a hepatitis B surface antigen-positive patient with adult T-cell leukemia-lymphoma after mogamulizumab monotherapy. **Hepatol Res**. 2024 Dec;54(12):1226-1233.
4. Fujii K, Inagaki A, Masaki A, Sugiura M, Suzuki T, **Ishida T**, Kusumoto S, Iida S, Inagaki H. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma. **Ann Hematol**. 2024 Jun;103(6):2041-2050.
5. Morishima S, Yoshimitsu M, Shindo T, Utsunomiya A, **Ishida T**, Ito A, Nakano N, Kawakita T, Eto T, Suehiro Y, Itonaga H, Mori Y, Miyazaki Y, Kanda J, Uchida N, Sawayama Y, Tomori S, Ichinohe T, Atsuta Y, Fukuda T, Kato K; ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy. Individual HLA affect survival after allogeneic stem cell transplantation in adult T-cell leukaemia/lymphoma. **HLA** 2024 Jun;103(6):e15555.

6. Hiramatsu H, Yokomori R, Shengyi L, Tanaka N, Mori S, Kiyotani K, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, Sanda T, **Ishida T.** Clinical landscape of TP73 structural variants in ATL patients. *Leukemia*. 2023 Dec;37(12):2502-2506. **(corresponding author)**
7. Hiramatsu H, Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Nishikawa H, Utsunomiya A, Ueda R, **Ishida T.** Landscape of immunoglobulin heavy chain γ gene class switch recombination in patients with adult T-cell leukemia-lymphoma. *Haematologica*. 2023 Apr 1;108(4):1173-1178. **(corresponding author)**
8. Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, **Ishida T.** Ito A, Iida S, Fukuhara N, Harigae H, Fujioka Y, Takahashi N, Wada H, Ishida F, Nakazawa H, Ishihara R, Murakami Y, Tagawa H, Matsuura T, Nakagawa S, Iwabuchi S, Hashimoto S, Imadome KI, Nakamura N, Ishizawa K, Kanda Y, Ando K, Kotani A. Hepatic niche leads to aggressive natural killer cell leukemia proliferation through transferrin-transferrin receptor 1 axis. *Blood*. 2023;142(4):352-364.
9. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, **Ishida T.** Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K. Validation of the iATL-PI prognostic index in therapeutic decision-making for patients with smoldering and chronic ATL: a multicenter study. *Int J Hematol*. 2023 Feb;117(2):206-215.
10. Tanaka N, Mori S, Kiyotani K, Ota Y, Gotoh O, Kusumoto S, Nakano N, Suehiro Y, Ito A, Choi I, Ohtsuka E, Hidaka M, Nosaka K, Yoshimitsu M, Imaizumi Y, Iida S, Utsunomiya A, Noda T, Nishikawa H, Ueda R, **Ishida T.** Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. *Haematologica*. 2022 Oct 1;107(10):2418-2431. **(corresponding author)**

11. Sakamoto Y, **Ishida T**, Masaki A, Murase T, Ohtsuka E, Takeshita M, Muto R, Iwasaki H, Ito A, Kusumoto S, Nakano N, Tokunaga M, Yonekura K, Tashiro Y, Iida S, Utsunomiya A, Ueda R, Inagaki H. CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. *Hematol Oncol*. 2022 Dec;40(5):876-884. **(corresponding author)**
12. Nosaka K, Kusumoto S, Nakano N, Choi I, Yoshimitsu M, Imaizumi Y, Hidaka M, Sasaki H, Makiyama J, Ohtsuka E, Jo T, Ogata M, Ito A, Yonekura K, Tatetsu H, Kato T, Kawakita T, Suehiro Y, Ishitsuka K, Iida S, Matsutani T, Utsunomiya A, Ueda R, **Ishida T**. Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab. *Br J Haematol*. 2022 Feb;196(3):629-638. **(corresponding author)**
13. Sakamoto Y, **Ishida T**, Masaki A, Takeshita M, Iwasaki H, Yonekura K, Tashiro Y, Ito A, Kusumoto S, Iida S, Utsunomiya A, Ueda R, Inagaki H. Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma. *Cancer Sci*. 2022 ;113(1):349-361.
14. Ong JZL, Yokomori R, Wong RWJ, Tan TK, Ueda R, **Ishida T**, Iida S, Sanda T. Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia. *Leukemia*. 2022 Sep;36(9):2293-2305.
15. Yoshimitsu M, Ando K, **Ishida T**, Yoshida S, Choi I, Hidaka M, Takamatsu Y, Gillings M, Lee GT, Onogi H, Tobinai K. Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy. *Jpn J Clin Oncol*. 2022;52(9):1014-1020.
16. Sakamoto Y, **Ishida T**, Masaki A, Murase T, Takeshita M, Muto R, Iwasaki H, Ito A, Kusumoto S, Nakano N, Tokunaga M, Yonekura K, Tashiro Y, Iida S, Utsunomiya A, Ueda R, Inagaki H. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma. *Br J Haematol*. 2021;195(4):571-584. **(corresponding author)**

17. Fujii K, Sakamoto Y, Masaki A, Murase T, Tashiro Y, Yonekura K, Utsunomiya A, Ito A, Kusumoto S, Iida S, Ueda R, **Ishida T**, Inagaki H. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma. *J Pathol Clin Res*. 2021 Jan;7(1):52-60. **(corresponding author)**
18. Sakamoto Y, **Ishida T**, Masaki A, Takeshita M, Iwasaki H, Kentaro Yonekura K, Tashiro Y, Ito A, Kusumoto S, Utsunomiya A, Iida S, Ueda R, Inagaki H. Clinical significance of *CD28* gene-related activating alterations in adult T-cell leukemia/lymphoma. *Br J Haematol*. 2021 Jan;192(2):281-291. **(corresponding author)**
19. Yonekura K, Kusumoto S, Choi I, Nakano N, Ito A, Suehiro Y, Imaizumi Y, Yoshimitsu M, Nosaka K, Ohtsuka E, Hidaka M, Jo T, Sasaki H, Moriuchi Y, Ogata M, Tatetsu H, Ishitsuka K, Miyazaki Y, Ueda R, Utsunomiya A, **Ishida T**. Mogamulizumab for adult T-cell leukemia-lymphoma: A multicenter prospective observational study. *Blood Adv*. 2020 Oct 27;4(20):5133-5145. **(corresponding author)**
20. Masaki A, **Ishida T**, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S. Clinical significance of tryptophan catabolism in follicular lymphoma. *Hematol Oncol*. 2020 Dec;38(5):742-753. **(corresponding author)**
21. Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Takahashi T, Morita A, Inagaki H, Iida S, and **Ishida T**. Robust CD8+ T cell proliferation and diversification after mogamulizumab in patients with adult T cell leukemia-lymphoma. *Blood Adv*. 2020 May 26;4(10):2180-2191. **(corresponding author)**
22. Wong R, Tan TK, Amanda S, Ngoc PCT, Leong WZ, Tan SH, Asamitsu K, Hibi Y, Ueda R, Okamoto T, **Ishida T**, Iida S, Sanda T. Feed-forward Regulatory Loop Driven by IRF4 and NF- κ B in Adult T-cell Leukemia/Lymphoma. *Blood*. 2020;135(12):934-947.

23. Totani H, Shinjo K, Suzuki M, Katsushima K, Mase S, Masaki A, Ito A, Ri M, Kusumoto S, Komatsu H, **Ishida T**, Inagaki H, Iida S. Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma. *Oncogene*. 2020 Aug;39(35):5782-5794.
24. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, **Ishida T**, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimar K, Tsukasaki K; for collaborative investigators. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study. *Cancer Sci*. 2020 Dec;111(12):4567-4580.
25. Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, Kusumoto S, Suzuki S, Hiura M, Takahashi T, Morita A, Inagaki H, Iida S, **Ishida T**. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma. *Clin Cancer Res*. 2019 Jul 15;25(14):4388-4399. **(corresponding author)**
26. **Ishida T**, Jo T, Takemoto S, Suzushima H, Suehiro Y, Choi I, Yoshimitsu M, Saburi Y, Nosaka K, Utsunomiya A, Kobayashi Y, Yamamoto K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Imada K, Kato K, Moriuchi Y, Yoshimura K, Takahashi T, Tobinai K, Ueda R. Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: Impact on allogeneic hematopoietic stem cell transplantation. *Br J Haematol*. 2019 Feb;184(3):479-483. **(corresponding author)**
27. Ito A, Suzuki Y, Masaki A, Yoshida S, Suzushima S, Takemoto S, Utsunomiya A, Ishii T, Hiura M, Takahashi T, Yurimoto S, Inagaki H, Morita A, Iida S, **Ishida T**. Quantitatively immunological characterization of mogamulizumab skin disorders in ATL patients. *J Cutan Immunol Allergy*. 2019;2:102-107
28. Sakamoto Y, Fujii K, Murase S, Nakano S, Masaki A, Murase T, Kusumoto S, Iida S, Utsunomiya A, Ueda R, **Ishida T**, Inagaki H. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma. *Int J Hematol*. 2019 Oct;110(4):389-392.

29. Yoshida T, Ri M, Fujinami H, Oshima Y, Tachita T, Marumo Y, Sasaki H, Kinoshita S, Totani H, Narita T, Masaki A, Ito A, Kusumoto S, **Ishida T**, Komatsu H, Iida S. Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma. *Int J Hematol*. 2019 Aug;110(2):228-236.
30. Yoshida T, Tachita T, Fujinami H, Oshima Y, Sasaki H, Marumo Y, Narita T, Ito A, Ri M, Kusumoto S, **Ishida T**, Komatsu H, Iida S. Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole. *Intern Med*. 2019 Aug 1;58(15):2219-2224.
31. Sasaki H, Mitani S, Kusumoto S, Marumo Y, Asano A, Yoshida T, Narita T, Ito A, Yano H, Ri M, **Ishida T**, Komatsu H, Iida S. Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation. *Int J Hematol*. 2019 Jul;110(1):119-123.
32. Cook L, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, Cwynarski K, Taylor G, Waldmann TA, Bittencourt A, Marcais A, Suarez F, Sibon D, Phillips A, Lunning M, Farid R, Imaizumi Y, Choi I, **Ishida T**, Ishitsuka K, Fukushima T, Uchamaru K, Takaori-Kondo A, Tokura Y, Utsunomiya A, Matsuoka M, Tsukasaki K, Watanabe T. A Revised Adult T-cell leukemia/lymphoma International Consensus Meeting Report. *J Clin Oncol*. 2019 Mar 10;37(8):677-687.
33. Sakamoto Y*, **Ishida T***, Masaki A, Murase T, Yonekura K, Tashiro Y, Tokunaga M, Utsunomiya A, Ito A, Kusumoto S, Iida S, Ueda R, and Inagaki H. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. *Blood* 2018;132(7):758-761. (**equally contributed*).
34. Kinoshita S, **Ishida T**, Ito A, Narita T, Masaki A, Suzuki S, Yoshida T, Ri M, Kusumoto S, Komatsu H, Shimizu N, Inagaki H, Kuroda T, Scholz A, Ueda R, Sanda T, Iida S. Cyclin-dependent kinase 9 as a potential specific molecular target in NK cell leukemia/lymphoma. *Haematologica*. 2018 Dec;103(12):2059-2068. (*corresponding author*).

35. Masaki A, Ishida T, Maeda Y, Ito A, Suzuki S, Narita T, Kinoshita S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Choi I, Suehiro Y, Iida S. Clinical significance of tryptophan catabolism in Hodgkin lymphoma. *Cancer Sci*. 2018;109:74-83. (*corresponding author*)
36. Masaki A, Ishida T, Suzuki S, Ito A, Narita T, Kinoshita S, Ri M, Kusumoto S, Komatsu H, Inagaki H, Ueda R, Iida S. HTLV-1 Tax-specific T cell exhaustion in HTLV-1-infected individuals. *Cancer Sci*. 2018;109:2383-2390. (*corresponding author*)
37. Ishitsuka K, Utsunomiya A, Ishida T. PD-1 Inhibitor Therapy in Adult T-Cell Leukemia–Lymphoma. *N Engl J Med*. 2018;379(7):695.
38. Wong RWJ, Ishida T, Sanda T. Targeting general transcriptional machinery as a therapeutic strategy for adult T-cell leukemia. *Molecules*. 2018, May 2;23(5).
39. Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S. Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting $\beta 2$ and $\beta 5$ subunits. *Oncotarget*. 2018 Jan 11;9(11):9975-9991.
40. Yoshida T, Ri M, Kinoshita S, Narita T, Totani H, Ashour R, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. *PLoS One*. 2018 May 8;13(5):e0196780.
41. Fuji S, Kato K, Nakano N, Ishida T, Ishitsuka K, Choi I, Matsuoka KI, Utsunomiya A. Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia lymphoma: A statement from key opinion leaders in Japan. *Adv Cell Gene Ther*. 2018;1:e5.

42. Kinoshita S, Ri M, Kanamori T, Aoki S, Yoshida T, Narita T, Totani H, Ito A, Kusumoto S, **Ishida T**, Komatsu H, Iida S. Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma. ***Oncol Lett.*** 2018 Jun;15(6):9450-9456.
43. Yoshimitsu M, Tanosaki R, Kato K, **Ishida T**, Choi I, Takatsuka Y, Fukuda T, Eto T, Hidaka M, Uchida N, Miyamoto T, Nakashima Y, Moriuchi Y, Nagafuji K, Miyazaki Y, Ichinohe T, Takanashi M, Atsuta Y, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Risk Assessment in Adult T-Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. ***Biol Blood Marrow Transplant.*** 2018;24(4):832-839.
44. Aiki S, Okuyama T, Sugano K, Kubota Y, Imai F, Nishioka M, Ito Y, Iida S, Komatsu H, **Ishida T**, Kusumoto S, Akechi T. Cognitive dysfunction among newly diagnosed older patients with hematological malignancy: frequency, clinical indicators and predictors. ***Jpn J Clin Oncol.*** 2018;48(1):61-67.
45. Narita T, **Ishida T**, Ito A, Masaki A, Kinoshita S, Suzuki S, Takino H, Yoshida T, Ri M, Kusumoto S, Komatsu H, Imada K, Tanaka Y, Takaori-Kondo A, Inagaki H, Scholz A, Lienau P, Kuroda T, Ueda R, Iida S. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. ***Blood.*** 2017;130(9):1114-1124 (***corresponding author***)
46. **Ishida T**, Utsunomiya A, Jo T, Yamamoto K, Kato K, Yoshida S, Takemoto S, Suzushima H, Kobayashi Y, Imaizumi Y, Yoshimura K, Kawamura K, Takahashi T, Tobinai K, Ueda R. Mogamulizumab for Relapsed Adult T-Cell Leukemia-Lymphoma: Updated Follow-up Analysis of Phase I and II Studies. ***Cancer Sci.*** 2017;108(10):2022-2029. (***corresponding author***)
47. Wong RWJ, Ngoc PCT, Leong WZ, Yam AWY, Zhang T, Asamitsu K, Iida S, Okamoto T, Ueda R, Gray NS, **Ishida T**, Sanda T. Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia. ***Blood*** 2017;130(21):2326-2338.

48. Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y, Amano M, **Ishida T**, Uike N, Utsunomiya A, Ohshima K, Kawai K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimarui K, Tsukasaki K. Epidemiological and clinical features of adult T-cell leukemia-lymphoma (ATL) in Japan, 2010-2011: a nationwide survey. *Cancer Sci.* 2017;108:2478-2486.
49. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, **Ishida T**, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T-Cell and NK/T-Cell Lymphomas: an International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2017;23:1826-1838.
50. Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki M, Ando K, Tsukasaki K, **Ishida T**, Kobayashi N, Ishizawa K, Tatsumi Y, Kato K, Kiguchi T, Ikezoe T, Laille E, Ro T, Tamakoshi H, Sakurai S, Ohtsu T. *Int J Hematol.* 2017;106:655-665.
51. Shinkai N, Kusumoto S, Murakami S, Ogawa S, Ri M, Matsui T, Tamori A, Toyoda H, **Ishida T**, Iida S, Tanaka Y. Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay. *Liver Int.* 2017 Aug;37(8):1138-1147.
52. Akechi T, Aiki S, Sugano K, Uchida M, Yamada A, Komatsu H, **Ishida T**, Kusumoto S, Iida S, Okuyama T. Does cognitive decline decrease health utility value in older adult patients with cancer? *Psychogeriatrics.* 2017 May;17(3):149-154.
53. **Ishida T**, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, Moriuchi Y, Jo T, Ishizawa K, Tobinai K, Tsukasaki K, Ito S, Yoshimitsu M, Otsuka M, Ogura M, Midorikawa S, Ruiz W, Ohtsu T. Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia-Lymphoma: ATLL-002. *J Clin Oncol.* 2016;34:4086-4093. (*corresponding author*).

54. Kato J, Masaki A, Fujii K, Takino H, Murase T, Yonekura K, Utsunomiya A, **Ishida T**, Iida S, Inagaki H. Quantitative PCR for HTLV-1 Provirus in Adult T-cell Leukemia/Lymphoma Using Paraffin Tumor Sections. *Pathol Int.* 2016;66(11):618-621.
55. Ogura M, **Ishida T**, Tsukasaki K, Takahashi T, Utsunomiya A. Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. *Cancer Chemother Pharmacol.* 2016 Jul;78(1):199-207.
56. Suzuki S, **Ishida T**, Yoshikawa K, Ueda R. Current status of immunotherapy. *Jpn J Clin Oncol.* 2016 Mar;46(3):191-203.
57. Totani H, Kusumoto S, Tanaka Y, Suzuki N, Hagiwara S, Kinoshita S, Iio E, Ito A, Ri M, **Ishida T**, Komatsu H, Iida S. The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy. *Int J Hematol.* 2016 Sep;104(3):384-391.
58. Totani H, Ri M, Kato C, Nakashima T, Suzuki N, Hagiwara S, Kanamori T, Murakami S, Masuda A, Kinoshita S, Yoshida T, Narita T, Ito A, Kusumoto S, **Ishida T**, Komatsu H, Iida S. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. *Int J Hematol.* 2016 Mar;103(3):316-321.
59. Suzuki T, Kusumoto S, Yamashita T, Masuda A, Kinoshita S, Yoshida T, Takami-Mori F, Takino H, Ito A, Ri M, **Ishida T**, Komatsu H, Ueda M, Ando Y, Inagaki H, Iida S. Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis. *Ann Hematol.* 2016;95(2):279-285.
60. Masaki A, **Ishida T**, Maeda Y, Suzuki S, Ito A, Takino H, Ogura H, Totani H, Yoshida T, Kinoshita S, Narita T, Ri M, Kusumoto S, Inagaki A, Komatsu H, Niimi A, Ueda R, Utsunomiya A, Inagaki H, Iida S. Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma. *Clin Cancer Res.* 2015;21:2830-2839. (*corresponding author*).

61. Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Uono H, Oka M, Ueda R, Nakayama E. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. *Clin Cancer Res.*, 2015 Oct 1;21(19):4327-4336.
62. Ishitsuka K, Utsunomiya A, Katsuya H, Takeuchi S, Takatsuka Y, Hidaka M, Sakai T, Yoshimitsu M, Ishida T, Tamura K. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma. *Cancer Sci.* 2015 Sep;106(9):1219-1223.
63. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive ATL: a randomized phase II study. *Br J Haematol.* 2015;169:672-682. (*corresponding author*).
64. Narita T, Ri M, Masaki A, Mori F, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy. *Blood Cancer J.* 2015 Dec 4;5:e373.
65. Okuyama T, Sugano K, Iida S, Ishida T, Kusumoto S, Akechi T. Screening Performance for Frailty Among Older Patients With Cancer: A Cross-Sectional Observational Study of Two Approaches. *J Natl Compr Canc Netw.* 2015 Dec;13(12):1525-1531.
66. Sugano K, Okuyama T, Iida S, Komatsu H, Ishida T, Kusumoto S, Uchida M, Nakaguchi T, Kubota Y, Ito Y, Takahashi K, Akechi T. Medical Decision-Making Incapacity among Newly Diagnosed Older Patients with Hematological Malignancy Receiving First Line Chemotherapy: A Cross-Sectional Study of Patients and Physicians. *PLoS One.* 2015 Aug 21;10(8):e0136163.

67. Ifuku H, Kusumoto S, Tanaka Y, Totani H, **Ishida T**, Okada M, Murakami S, Mizokami M, Ueda R, Iida S, Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. *Hepatol Res.* 2015;101(4):398-404.
68. Totani H, Kusumoto S, **Ishida T**, Masuda A, Yoshida T, Ito A, Ri M, Komatsu H, Murakami S, Mizokami M, Ueda R, Niimi A, Inagaki H, Tanaka Y, Iida S. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy. *Int J Hematol.* 2015 Apr;101(4):398-404.
69. Suzuki T, Kusumoto S, Masaki A, **Ishida T**, Inagaki H, Iida S, Mori F. CD30-positive primary bone marrow lymphoma mimicking Hodgkin lymphoma. *Int J Hematol.* 2015 Feb;101(2):109-111.
70. Narita T, **Ishida T**, Masaki A, Suzuki S, Ito A, Mori F, Yamada T, Masaki Ri, Kusumoto S, Komatsu H, Miyazaki Y, Takatsuka Y, Utsunomiya A, Niimi A, Iida S, Ueda R. HTLV-1 bZIP factor specific CD4 T cell responses in ATL patients after allogeneic hematopoietic stem cell transplantation. *J Immunol.* 2014 Feb 1;192:940-947. (*corresponding author*)
71. Ogura M*, **Ishida T***, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. *J Clin Oncol.* 2014 Apr 10;32(11):1157-1163. (**equally contributed*)
72. Nakano N, Kusumoto S, Tanaka Y, **Ishida T**, Takeuchi S, Takatsuka Y, Akinaga S, Mizokami M, Ueda R, Utsunomiya A. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. *Hepatol Res.* 2014 Mar;44(3):354-357.

73. Mori F, **Ishida T**, Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, Ueda R, Inagaki H, Iida S. Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model. *Eur J Haematol*. 2014 Mar;92(3):219-228. **(corresponding author)**
74. Xia H, Yamada S, Aoyama M, Sato F, Masaki A, Ge Y, Ri M, **Ishida T**, Ueda R, Utsunomiya A, Asai K, Inagaki H. Prognostic impact of miR-145 down-regulation in adult T-cell leukemia/lymphoma. *Hum Pathol*. 2014 Jun;45(6):1192-1198.
75. **Ishida T**, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, Morita A, Akinaga S, Ueda R. Stevens-Johnson Syndrome associated with mogamulizumab treatment of Adult T-cell leukemia/lymphoma. *Cancer Sci*. 2013; 104:647-650. **(corresponding author)**
76. **Ishida T**, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, Eto T, Miyazaki Y, Hidaka M, Uike N, Miyamoto T, Tsudo M, Sakamaki H, Morishima Y, Suzuki R, Utsunomiya A, et al. Impact of GVHD on allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study Biology of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2013;19:1731-1739. **(corresponding author)**
77. Suzuki T, Kusumoto S, Yoshida T, Mori F, Ito A, Ri M, **Ishida T**, Komatsu H, Niimi A, Iida S. Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation. *Int J Hematol*. 2013;97:540-543.
78. Masaki A, **Ishida T**, Suzuki S, Ito A, Mori F, Sato F, Narita T, Yamada T, Ri M, Kusumoto S, Komatsu H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R. Autologous Tax-specific CTL therapy in a primary ATL cell-bearing NOD/Shi-scid, IL-2R γ ^{null} mouse model. *J Immunol*. 2013;191(1):135-144.. **(corresponding author)**

79. Sato F, Ishida T, Ito A, Mori F, Masaki A, Takino H, Narita T, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R, Inagaki H, Iida S. Angioimmunoblastic T-cell lymphoma mice model. *Leuk Res.* 2013;37:21-27. **(corresponding author)**
80. Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H, Masaki A, Yoshida T, Mori F, Ito A, Yano H, Ri M, Kayukawa S, Kataoka T, Kusumoto S, Ishida T, Hayami Y, Hanamura I, Komatsu H, Inagaki H, Matsuda Y, Ueda R, Iida S. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. *Leuk Res.* 2013;37:1648-1655.
81. Miyazaki Y, Fujiwara H, Asai H, Ochi F, Ochi T, Azuma T, Ishida T, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M. Development of a novel redirected T cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. *Blood.* 2013 Jun 13;121(24):4894-4901.
82. Kato H, Saito C, Ito E, Furuhashi T, Nishida E, Ishida T, Ueda R, Inagaki H, Morita A. Bath-PUVA Therapy Decreases Infiltrating CCR4-Expressing Tumor Cells and Regulatory T Cells in Patients With Mycosis Fungoides. *Clin Lymphoma Myeloma Leuk.* 2013 Jun;13(3):273-280.
83. Suzuki S, Masaki A, Ishida T, Ito A, Mori F, Sato F, Narita T, Ri M, Kusumoto S, Komatsu H, Fukumori Y, Nishikawa H, Tanaka Y, Niimi A, Inagaki H, Iida S, Ueda R. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. *Cancer Sci.* 2012;103:1764-1773. **(corresponding author)**
84. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. *J Clin Oncol*, 2012; 30:837-842. **(corresponding author)**

85. **Ishida T.** Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, Eto T, Takatsuka Y, Miyazaki Y, Moriuchi Y, Hidaka M, Akashi K, Uike N, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishiyama T, Utsunomiya A. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. *Blood*. 2012 Aug 23;120(8):1734-1741. **(corresponding author)**
86. *Nishikawa H, *Maeda Y, ***Ishida T.** Gnjjatic S, Sato E, Mori F, Sugiyama D, Ito A, Fukumori Y, Utsunomiya A, Inagaki H, Old LJ, Ueda R, Sakaguchi S. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. *Blood* 2012;119:3097-3104. **(*equally contributed)**
87. Mori F, **Ishida T.** Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S. Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. *Blood Cancer J*. 2012 Apr;2(4):e67. **(corresponding author)**
88. Ri M, Tashiro E, Oikawa D, Shinjo S, Tokuda M, Yokouchi Y, Narita T, Masaki A, Ito A, Ding J, Kusumoto S, **Ishida T.** Komatsu H, Shiotsu Y, Ueda R, Iwawaki T, Imoto M, Iida S. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. *Blood Cancer J*. 2012 Jul;2(7):e79.
89. Yamada S, Sato F, Xia H, Takino H, Kominato S, Ri M, **Ishida T.** Iida S, Inagaki H, Yamada K. Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specified. *Hum Pathol*. 2012;43:1322-1327.
90. **Ishida T.** Ueda R. Immunopathogenesis of lymphoma: Focus on CCR4. *Cancer Sci*. 2011;102:44-50. **(corresponding author)**
91. **Ishida T.** Ueda R. Antibody therapy for Adult T-cell leukemia-lymphoma. *Int J Hematol*,2011;94(5):443-452. **(corresponding author)**

92. Shimizu K, Murakami H, Sawamura M, Hattori Y, Okamoto S, Miwa A, Sugiura I, Shimazaki C, Taniwaki M, Ishida T, Hayashi T, Kosugi H, Yuge M, Iida S, **Ishida T**, Sunami K, Asaoku H, Sakai A, Abe M, Takagi T. Efficacy of Long-Term Treatment with Low-Dose Thalidomide for Patients with Relapsed/Refractory Multiple Myeloma. *International Journal of Clinical Medicine* 2011;2:570-575.
93. Sato F, Ito A, **Ishida T**, Mori F, Takino H, Inagaki A, Ri M, Kusumoto S, Komatsu H, Iida S, Okada N, Inagaki H, Ueda R. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2R γ (null) mouse lymphoma model. *Cancer Immunol Immunother.* 2010;59:1791-1800. **(corresponding author)**
94. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, Ito A, Inagaki A, Kusumoto S, **Ishida T**, Komatsu H, Shiotsu Y, Ueda R. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. *Leukemia.* 2010;24:1506-1512.
95. Yoshida T, Kusumoto S, Inagaki A, Mori F, Ito A, Ri M, **Ishida T**, Komatsu H, Iida S, Sugauchi F, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. *Int J Hematol.* 2010;91:844-849.
96. Ishii T, **Ishida T**, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, Shitara K, Ueda R. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma (ATLL). *Clin Cancer Res.* 2010;16:1520-1531. **(corresponding author)**
97. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, **Ishida T**, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R. Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients with Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma. *J Clin Oncol.* 2010;28:1591-1598.

98. Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, Mori F, Ri M, Ito A, Wakita A, **Ishida T**, Nitta M, Ueda R. The Asn505 mutation of c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. *Blood*. 2009;114:3325-3328.
99. Ito A, **Ishida T**, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL Cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2Rgamma(null) mice in vivo. *J Immunol*. 2009;183: 4782-4791. *(corresponding author)*
100. Inagaki A, **Ishida T**, Yano H, Ishii T, Kusumoto S, Ito A, Ri M, Mori F, **Ding J**, Komatsu H, Iida S, Ueda R. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. *Int J Cancer*. 2009;125:212-221. *(corresponding author)*
101. Ri M, Iida S, **Ishida T**, Ito A, Yano H, Inagaki A, Ding J, Kusumoto S, Komatsu H, Utsunomiya A, Ueda R. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. *Cancer Sci*. 2009;100:341-348.
102. Ito A, **Ishida T**, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. *Cancer Immunol Immunother*. 2009;58: 1195-1206. *(corresponding author)*
103. Yano H, Kayukawa S, Iida S, Nakagawa C, Oguri T, Sanda T, Ding J, Mori F, Ito A, Ri M, Inagaki A, Kusumoto S, **Ishida T**, Komatsu H, Inagaki H, Suzuki A, Ueda R. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. *Cancer Sci*. 2008;99:2309-2314.

104. Yano H, **Ishida T**, Imada K, Sakai T, Ishii T, Inagaki A, Iida S, Uchiyama T, Ueda R. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. *Br J Haematol.* 2008;140:586-589. **(corresponding author)**
105. Yano H, **Ishida T**, Inagaki A, Ishii T, Ding J, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R. Defucosylated anti -CCR4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/ refractory mycosis fungoides and sezary syndrome. *Clin Cancer Res.* 2007;13:6494-6500. **(corresponding author)**
106. Yano H, **Ishida T**, Inagaki A, Ishii T, Kusumoto S, Komatsu H, Iida S, Utsunomiya A, Ueda R. Regulatory T-cell Function of adult T-cell leukemia/lymphoma cells. *Int J Cancer.* 2007; 120:2052-2057. **(corresponding author)**
107. Li C, Takino H, Eimoto T, **Ishida T**, Inagaki A, Ueda R, Suzuki R, Yoshino T, Nakagawa A, Nakamura S, Inagaki H. Prognostic Significance of NPM-ALK Fusion Transcript Overexpression in ALK-positive Anaplastic Large Cell Lymphoma. *Mod Pathol.* 2007;20: 648-655.
108. Utsunomiya A, **Ishida T**, Inagaki A, Ishii T, Yano H, Komatsu H, Iida S, Yonekura K, Takeuchi S, Takatsuka Y, Ueda R. Clinical Significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. *Leuk Res.* 2007;31:915-920. **(corresponding author)**
109. **Ishida T**, Ishii T, Inagaki A, Yano H, Kusumoto S, Ri M, Komatsu H, Iida S, Inagaki H, Ueda R. The CCR4 as a novel specific molecular target for immunotherapy in Hodgkin lymphoma. *Leukemia.* 2006; 20: 2162-2168. **(corresponding author)**
110. **Ishida T**, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. *Cancer Sci.* 2006;97:1139-1146.

111. **Ishida T**, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. *Cancer Res.* 2006;66:5716-5722. **(corresponding author)**
112. Inagaki A, **Ishida T**, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. *Int J Cancer.* 2006;118:3054-3061.
113. **Ishida T**, Inagaki H, Kusumoto S, Inagaki A, Komatsu H, Iida S, Harada S, Takeuchi G, Ueda R. CC chemokine receptor 4-positive diffuse large B-cell lymphoma involving the skin: a case report. *Int J Hematol.* 2005;82:148-151. **(corresponding author)**
114. Kusumoto S, Kobayashi Y, Sekiguchi N, Tanimoto K, Onishi Y, Yokota Y, Watanabe T, Maeshima AM, **Ishida T**, Inagaki H, Matsuno Y, Ueda R, Tobinai K. Diffuse large B-cell lymphoma with extra Bcl-2 gene signals detected by FISH analysis is associated with a "non-germinal center phenotype". *Am J Surg Pathol.* 2005;29:1067-1073.
115. Uranishi M, Iida S, Sanda T, **Ishida T**, Tajima E, Ito M, Komatsu H, Inagaki H, Ueda R. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy. *Leukemia.* 2005;19:1471-1478.
116. Sanda T, Kuwano T, Nakao S, Iida S, Ishida T, Komatsu H, Shudo K, Kuwano M, Ono M, Ueda R. Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis. *Leukemia.* 2005;19:901-909.
117. **Ishida T**, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. *Clin Cancer Res.* 2004;10:7529-7539.

118. **Ishida T**, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, Takeuchi G, Eimoto T, Nakamura S, Ueda R. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. *Clin Cancer Res.* 2004;10:5494-5500.
119. **Ishida T**, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shimizu S, Ito M, Komatsu H, Wakita A, Eimoto T, Matsushima K, Ueda R. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. *Clin Cancer Res.* 2003;9:3625-3634.
120. Miura K, Iida S, Hanamura I, Kato M, Banno S, **Ishida T**, Kusumoto S, Takeuchi G, Miwa H, Nitta M, Inagaki H, Eimoto T, Nomura K, Taniwaki M, Ueda R. Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia. *Cancer Sci.* 2003;94:350-354.

September 18. 2025 T. Ishida